Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
88
Recruiting, industry sponsors, Infectious disease and vaccines, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,960
88 trials
Showing 1 to 25, recently updated first.
AusperBio Therapeutics Inc.Industry
NCT07370207 · 84 participants (planned) · Start Mar 6, 2026 · Primary completion Dec 31, 2028
Drug: AHB-137 · For: Hepatitis B, Chronic
Sites: Fitzroy, Australia; Hong Kong, China; Musashino, Japan · 9 sites in all
PfizerPfizer (PFE)
NCT06462235 · 48 participants (planned) · Start Sep 25, 2024 · Primary completion Apr 25, 2027
Drug: Part A: ATM-AVI Single Dose, Cohorts 1-4; Part B: Multiple-dose ATM-AVI, Cohorts 1-4 · For: Gram-negative Bacterial Infection
Sites: Orange, California; Aurora, Colorado; Indianapolis, Indiana · 36 sites in all
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsRecruiting
AusperBio Therapeutics Inc.Industry
NCT07654283 · 70 participants (planned) · Start Sep 1, 2026 · Primary completion Nov 11, 2027
Drug: AHB-137 · For: Hepatitis B, Chronic
Sites: Redwood City, California; Baltimore, Maryland; New York, New York · 10 sites in all
- Safety and Efficacy of SUM-191 for Patients With Bacterial ConjunctivitisPivotal-lookingRecruiting
Senju USA, Inc.Industry
NCT07565103 · 426 participants (planned) · Start Jun 25, 2026 · Primary completion Aug 15, 2028
Drug: SUM-191; Placebo · For: Bacterial Conjunctivitis
Sites: Delray Beach, Florida; Austin, Texas
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)Pivotal-lookingRecruiting
Spyre Therapeutics, Inc.Industry
NCT07766005 · 150 participants (planned) · Start Oct 6, 2026 · Primary completion Oct 2027
Drug: SPY072; Placebo and 1 more · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Rogers, Arkansas; Irvine, California · 34 sites in all
- Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or OlderPivotal-lookingRecruiting
GC Biopharma CorpIndustry
NCT07883928 · 1,806 participants (planned) · Start Oct 12, 2026 · Primary completion Mar 2028
Drug: vaccination of GC3114B; Vaccination of Efluelda · For: Influenza A, Influenza B; Influenza Vaccination
Sites: Seoul, South Korea
Incyte CorporationIncyte (INCY)
NCT07213973 · 40 participants (planned) · Start Feb 2, 2026 · Primary completion Mar 25, 2028
Drug: Povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Farmington, Connecticut · 28 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07850609 · 80 participants (planned) · Start Oct 27, 2026 · Primary completion Dec 2, 2027
Drug: Alimatravir · For: HIV
Sites: San Francisco, California; Washington D.C., District of Columbia; Boston, Massachusetts · 7 sites in all
- A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)Pivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT07202546 · 186 participants (planned) · Start Feb 11, 2026 · Primary completion Oct 28, 2027
Drug: VH4524184; Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets and 1 more · For: HIV Infections
Sites: Bakersfield, California; Palm Springs, California; West Hollywood, California · 125 sites in all
- Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal AntibodyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07285213 · 230 participants (planned) · Start Dec 10, 2025 · Primary completion Apr 20, 2027
Drug: AZD5148 · For: Clostridioides Difficile Infection
Sites: Phoenix, Arizona; Chula Vista, California; Sacramento, California · 117 sites in all
- Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)Pivotal-lookingRecruiting
Serum Institute of India Pvt. Ltd.Industry
NCT07855172 · 186 participants (planned) · Start Nov 1, 2026 · Primary completion Oct 2027
Drug: Hexavalent (DTwP-HepB-rPV-Hib) Vaccine; HEXASIIL · For: Diptheria Immunization; Tetanus Immunization; Pertussis Immunization and 3 more
Sites: Dhaka, Bangladesh
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07830329 · 300 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 24, 2028
Drug: Olatorepatide; Placebo · For: Hidradenitis Suppurativa
Sites: The Bronx, New York
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgePivotal-lookingRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07808697 · 300 participants (planned) · Start Sep 4, 2026 · Primary completion Aug 30, 2029
Drug: mRNA-1283; mRNA-1273 · For: SARS-CoV-2
Sites: Ontario, California; Miami, Florida; Miami Lakes, Florida · 31 sites in all
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07266831 · 570 participants (planned) · Start Dec 18, 2025 · Primary completion Feb 1, 2029
Drug: ISL; ULO and 4 more · For: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Sites: Los Angeles, California; Denver, Colorado; Washington D.C., District of Columbia · 56 sites in all
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseasePivotal-lookingRecruiting
Enanta Pharmaceuticals, IncIndustry
NCT07908381 · 860 participants (planned) · Start Oct 19, 2026 · Primary completion Jul 2029
Drug: zelicapavir; Placebo · For: RSV
Sites: Cape Coral, Florida; Miami, Florida; Bluffton, South Carolina · 4 sites in all
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
Oruka Therapeutics, Inc.Industry
NCT07783542 · 200 participants (planned) · Start Aug 21, 2026 · Primary completion Oct 2028
Drug: ORKA-002 · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 25 sites in all
PfizerPfizer (PFE)
NCT05639647 · 48 participants (planned) · Start Apr 18, 2023 · Primary completion Mar 31, 2027
Drug: ATM-AVI; BAT · For: Gram-negative Bacterial Infections
Sites: San Diego, California; New York, New York; Beijing, China · 22 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04375800 · 84 participants (planned) · Start Feb 3, 2021 · Primary completion Nov 12, 2028
Drug: Doravirine; 2 NRTIs and 1 more · For: Human Immunodeficiency Virus (HIV) Infection
Sites: Aurora, Colorado; Atlanta, Georgia; Rionegro, Colombia · 26 sites in all
- A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)Pivotal-lookingRecruiting
Changchun BCHT Biotechnology Co.Industry
NCT07894055 · 420 participants (planned) · Start Aug 12, 2026 · Primary completion Sep 25, 2026
Drug: Tdap vaccine; Placebo · For: Pertussis (Whooping Cough); Diphtheria; Tetanus
Sites: Lishui, China
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)Pivotal-lookingRecruiting
Brii Biosciences LimitedIndustry
NCT06650852 · 250 participants (planned) · Start Oct 31, 2024 · Primary completion Sep 2028
Drug: BRII-179; BRII-835 (VIR-2218) and 3 more · For: Chronic Hepatitis B Virus (HBV) Infection
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 14 sites in all
- A Study of BLB-201 RSV Vaccine in Infants and ChildrenPivotal-lookingRecruiting
Blue Lake Biotechnology Inc.Industry
NCT05655182 · 137 participants (planned) · Start Mar 9, 2023 · Primary completion Dec 30, 2028
Drug: PIV5-vectored RSV Vaccine (BLB-201) Low Dose; PIV5-vectored RSV Vaccine (BLB-201) High Dose and 1 more · For: Respiratory Syncytial Virus Infections
Sites: La Mesa, California; Modesto, California; San Diego, California · 18 sites in all
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe DiseasePivotal-lookingRecruiting
ShionogiIndustry
NCT07214571 · 192 participants (planned) · Start Dec 11, 2025 · Primary completion Dec 30, 2026
Drug: S-337395; Placebo · For: Respiratory Syncytial Virus Infections
Sites: Los Angeles, California; Modesto, California; Toluca Lake, California · 89 sites in all
- Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)Pivotal-lookingRecruiting
CSL BehringIndustry
NCT07048262 · 180 participants (planned) · Start Sep 3, 2025 · Primary completion May 6, 2029
Drug: CSL787; Placebo · For: Non-cystic Fibrosis Bronchiectasis
Sites: Queensland, Australia; Westmead, Australia; Chikushino-shi, Japan · 13 sites in all
- Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07810010 · 8,000 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 3, 2028
Drug: Bivalent RSV+HMPV protein vaccine; Placebo · For: Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers
Sites: Bruse, Australia; Blacktown, Australia; Maroubra, Australia · 21 sites in all
- A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07225569 · 144 participants (planned) · Start Dec 29, 2025 · Primary completion Sep 22, 2027
Drug: SAR445399; Placebo · For: Hidradenitis Suppurativa
Sites: Scottsdale, Arizona; North Hollywood, California; Boynton Beach, Florida · 86 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.